Cytokinetics (CYTK)
Cytokinetics Market Cap: 69.51M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYTK Market Cap Rankings
| Overall | 19th percentile | 3755 of 4651 |
| Sector | 25th percentile | 393 of 526 in Healthcare |
| Industry | 26th percentile | 120 of 163 in Biotechnology |
CYTK Market Cap Range, Past 5 Years
| Minimum | 69.39M | Dec 2011 |
| Maximum | 321.58M | Sep 2009 |
| Average | 161.06M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these CYTK related companies
CYTK News
$CYTK forms bearish "Continuation Diamond" chart pattern. http://stks.co/3aqN
about 25 days ago by RecogniaEvents
about 25 days ago by RecogniaEvents
@Jamtrades @seekingalpha when they use the term encouiraging it usually means its crap $CYTK
about 30 days ago by lieberlanz
about 30 days ago by lieberlanz
Cytokinetics (CYTK) Proposed Muscle Troponin Activator Now on FDA's Fast Track
Apr 19, 8:53AM Street Insider
Apr 19, 8:53AM Street Insider
$CYTK forms bearish "Head and Shoulders Top" chart pattern. http://stks.co/3IOW
about 45 days ago by RecogniaEvents
about 45 days ago by RecogniaEvents
$CYTK filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3BjU
about 53 days ago by MarketBrief
about 53 days ago by MarketBrief
Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference
Mar 27, 4:13PM Marketwire
Mar 27, 4:13PM Marketwire
@ChiBullsTrader @ChillzTrading Agree! May add position for that event; already have $CYTK for the same conference.
about 65 days ago by Chilltill
about 65 days ago by Chilltill
$CYTK forms bullish "Diamond Bottom" chart pattern. http://stks.co/2kad
about 77 days ago by RecogniaEvents
about 77 days ago by RecogniaEvents
Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Feb 02, 4:13PM Street Insider
Feb 02, 4:13PM Street Insider
Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Feb 02, 4:00PM Marketwire
Feb 02, 4:00PM Marketwire
Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012
Jan 26, 4:00PM Marketwire
Jan 26, 4:00PM Marketwire
Cytokinetics (CYTK) Reports Positive CK-2017357 Phase II, Part A Dat in ALS Patients
Nov 30, 7:32AM Street Insider
Nov 30, 7:32AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTK | 0.91 | -0.01 | -1.09% | 70.27M |
| CYN | 50.57 | +0.89 | +1.79% | 2.644B |
| CY | 13.25 | +0.31 | +2.40% | 2.004B |
| CXM | 0.2381 | +0.00 | +0.21% | 28.48M |
| CWTR | 0.84 | +0.01 | +1.20% | 100.94M |
| CWI | 27.64 | -0.14 | -0.50% | |
| CWCO | 7.63 | -0.08 | -1.04% | 112.33M |
| CVY | 20.83 | +0.01 | +0.05% | |
| CVS | 45.05 | -0.12 | -0.27% | 59.02B |
| CVM | 0.419 | -0.02 | -5.31% | 113.20M |
